Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.00 USD
−117.25 M USD
0.00 USD
28.14 M
About Biomea Fusion, Inc.
Sector
CEO
Thomas Butler
Headquarters
Redwood City
Website
Founded
2017
FIGI
BBG00YS4WDC9
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BMEA is 6.38 USD — it has decreased by −2.18% in the past 24 hours. Watch Biomea Fusion, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Biomea Fusion, Inc. stocks are traded under the ticker BMEA.
BMEA stock has fallen by −21.70% compared to the previous week, the month change is a −46.09% fall, over the last year Biomea Fusion, Inc. has showed a −35.94% decrease.
We've gathered analysts' opinions on Biomea Fusion, Inc. future price: according to them, BMEA price has a max estimate of 128.00 USD and a min estimate of 11.00 USD. Watch BMEA chart and read a more detailed Biomea Fusion, Inc. stock forecast: see what analysts think of Biomea Fusion, Inc. and suggest that you do with its stocks.
BMEA reached its all-time high on Jun 8, 2023 with the price of 43.69 USD, and its all-time low was 2.84 USD and was reached on May 2, 2022. View more price dynamics on BMEA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BMEA stock is 6.70% volatile and has beta coefficient of 1.41. Track Biomea Fusion, Inc. stock price on the chart and check out the list of the most volatile stocks — is Biomea Fusion, Inc. there?
Today Biomea Fusion, Inc. has the market capitalization of 227.58 M, it has decreased by −11.67% over the last week.
Yes, you can track Biomea Fusion, Inc. financials in yearly and quarterly reports right on TradingView.
Biomea Fusion, Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
BMEA earnings for the last quarter are −0.91 USD per share, whereas the estimation was −0.94 USD resulting in a 3.65% surprise. The estimated earnings for the next quarter are −0.92 USD per share. See more details about Biomea Fusion, Inc. earnings.
Biomea Fusion, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
BMEA net income for the last quarter is −32.79 M USD, while the quarter before that showed −37.28 M USD of net income which accounts for 12.04% change. Track more Biomea Fusion, Inc. financial stats to get the full picture.
No, BMEA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 103.00 employees. See our rating of the largest employees — is Biomea Fusion, Inc. on this list?
Like other stocks, BMEA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Biomea Fusion, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Biomea Fusion, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Biomea Fusion, Inc. stock shows the strong sell signal. See more of Biomea Fusion, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.